Following an emergency warning from WHO, the European Union granted sales authorization for the monkeypox virus vaccine.
World After the World Health Organization (WHO) declared the rapidly spreading monkeypox virus a worldwide emergency, the European Commission allowed the sale of the Imvanex vaccine developed against the virus.
The WHO in its decision on Saturday defined the monkeypox virus outbreak as an “international dangerous emergency” in the context of public health. This ability of the organization makes it easy to respond in a coordinated manner against the pandemic.
The European Commission has authorized the sale of Imvanex vaccine as an effective vaccine against monkeypox virus as of yesterday, according to a statement made today by Denmark-based biotechnology company Bavarian Nordic BAVA.CO. The European Union previously only allowed the use of a vaccine against smallpox.
abd And Canada previously allowed the use of a vaccine against the monkeypox virus.
Paul Chaplin, CEO of Bavarian Nordic, said: “The availability of an approved vaccine can enhance countries’ preparedness to deal with emerging diseases. But this can only be achieved through investment and structural planning for biological preparations.” Shares of Bavarian Nordic rose 122% over the past three months on anticipation of demand for the monkey virus smallpox vaccine.